GPD1 and colorectal cancer: No significant association was observed for GPD1 (OR: 1.00, 95% CI: 0.74-1.36; p = 0.98).<h4>Conclusions</h4>Metformin may prevent colorectal cancer via the AMPKγ1 (PRKAG1) target based on genetic evidence, supporting the evaluation of metformin use in colorectal cancer prevention using randomised controlled trials.